E-LIB Suche - Ergebnisse für: Smit, E.F.

1

Antibody–drug conjugates in lung and breast cancer: current..:

Peters, S. ; Loi, S. ; André, F....
Annals of Oncology. 35 (2024) 7 - p. 607-629 , 2024

Link: https://doi.org/10.1016/..

2

Integrated noninvasive diagnostics for prediction of surviv..:

Yeghaian, M. ; Bodalal, Z. ; Tareco Bucho, T.M....
Immuno-Oncology and Technology. 24 (2024) - p. 100723 , 2024

Link: https://doi.org/10.1016/..

3

267MO Pooled analysis of trastuzumab deruxtecan (T-DXd) ret..:

Rugo, H.S. ; Tokunaga, E. ; Iwata, H....
ESMO Open. 9 (2024) - p. 103326 , 2024

Link: https://doi.org/10.1016/..

4

Translational insights and overall survival in the U31402-A..:

Yu, H.A. ; Baik, C. ; Kim, D.-W....
Annals of Oncology. 35 (2024) 5 - p. 437-447 , 2024

Link: https://doi.org/10.1016/..

5

MA13.10 Trastuzumab Deruxtecan in Patients with HER2-Mutant..:

Janne, P. ; Goto, Y. ; Kubo, T....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S148 , 2023

Link: https://doi.org/10.1016/..

6

PP01.48 Efficacy and Safety of Patritumab Deruxtecan (HER3-..:

Johnson, M.L. ; Steuer, C.E. ; Hayashi, H....
Journal of Thoracic Oncology. 18 (2023) 3 - p. e30-e31 , 2023

Link: https://doi.org/10.1016/..

7

P2.10-07 ORA-LM: Molecular Analysis in Cerebrospinal Fluid ..:

van der Wel, T. ; Boelens, M.C. ; Jebbink, M....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S354-S355 , 2023

Link: https://doi.org/10.1016/..

8

Trastuzumab-Emtansine and Osimertinib Combination Therapy t..:

Jebbink, M. ; de Langen, A.J. ; Monkhorst, K....
JTO Clinical and Research Reports. 4 (2023) 4 - p. 100481 , 2023

Link: https://doi.org/10.1016/..

9

One-year data on immunogenicity and breakthrough infections..:

van der Veldt, A.A.M. ; Oosting, S.F. ; Fehrmann, R.S.N....
ESMO Open. 8 (2023) 1 - p. 100785 , 2023

Link: https://doi.org/10.1016/..

10

RWD121 Moment Registry (MET NON SMALL CELL CANCER REGISTRY)..:

Thomas, M. ; Christopoulos, P. ; Iams, W.T....
Value in Health. 26 (2023) 12 - p. S527 , 2023

Link: https://doi.org/10.1016/..

11

Factors associated with long-term antibody response after C..:

Oosting, S.F. ; van der Veldt, A.A.M. ; Fehrmann, R.S.N....
ESMO Open. 8 (2023) 4 - p. 101599 , 2023

Link: https://doi.org/10.1016/..

12

A comprehensive overview of the heterogeneity of EGFR exon ..:

Zwierenga, Fenneke ; van Veggel, Bianca A.M.H. ; van den Berg, Anke...
Cancer Treatment Reviews. 120 (2023) - p. 102628 , 2023

Link: https://doi.org/10.1016/..

13

99P The optimal treatment for patients with stage I non-sma..:

de Ruiter, J. ; van der Noort, V. ; van Diessen, J....
Journal of Thoracic Oncology. 18 (2023) 4 - p. S98 , 2023

Link: https://doi.org/10.1016/..

14

PPD02.03 Tepotinib in Patients with MET Exon 14 (METex14) S..:

Garassino, M.C. ; Thomas, M. ; Felip, E....
Journal of Thoracic Oncology. 18 (2023) 3 - p. e7-e8 , 2023

Link: https://doi.org/10.1016/..

15

34P Treatment sequencing in the VISION study of tepotinib i..:

Griesinger, F. ; Garassino, M.C. ; Felip, E....
Journal of Thoracic Oncology. 18 (2023) 4 - p. S60-S61 , 2023

Link: https://doi.org/10.1016/..